Compare MBOT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBOT | SPRO |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 73.4M |
| IPO Year | 2000 | 2017 |
| Metric | MBOT | SPRO |
|---|---|---|
| Price | $1.03 | $1.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $6.33 | $5.00 |
| AVG Volume (30 Days) | 619.4K | ★ 826.9K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.27 | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | $116,887.00 | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $475.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $1.03 | $1.08 |
| 52 Week High | $3.04 | $3.08 |
| Indicator | MBOT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 20.59 | 45.45 |
| Support Level | N/A | $1.10 |
| Resistance Level | $2.21 | $1.28 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 4.62 | 16.67 |
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.